Nasivin Zatoki I Katar (Pseudoephedrine Hydrochloride, Ibuprofen)

Pseudoephedrine hydrochloride and ibuprofen, the active ingredients in Nasivin Zatoki I Katar, are a decongestant and a non‑steroidal anti‑inflammatory drug presented as an oral tablet for systemic use. It relieves nasal congestion, pain and fever associated with upper respiratory infections in adults and children.

GNH USA supplies Nasivin Zatoki I Katar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nasivin Zatoki I Katar combines a decongestant and an NSAID to address symptoms of upper respiratory tract conditions.

- Nasal congestion due to cold or sinusitis: reduces swelling of nasal mucosa and eases breathing. - Headache associated with sinus pressure: alleviates pain through anti‑inflammatory action. - Fever in respiratory infections: lowers body temperature by inhibiting prostaglandin synthesis. - General pain from upper respiratory tract infections: provides analgesic relief.

Common Side Effects: - Dry mouth - Nausea - Dizziness - Insomnia

Serious or Rare Side Effects: - Elevated blood pressure or hypertension - Severe allergic reactions such as anaphylaxis, rash or facial swelling - Gastrointestinal bleeding, ulceration or perforation

Before using this product, consider the following precautions: - Cardiovascular risk: avoid in patients with uncontrolled hypertension or serious heart disease. - Pregnancy and lactation: consult a healthcare professional before use. - Drug interactions: review concomitant medications, especially MAO inhibitors or anticoagulants. - Underlying conditions: use cautiously in patients with glaucoma, diabetes or thyroid disorders. - Pediatric use: limit to children as directed by a prescriber. - Store at ambient temperature: keep below 25°C, retain original packaging and protect from moisture.

Nasivin Zatoki I Katar may interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis when combined with pseudoephedrine. - Anticoagulants (e.g., warfarin, DOACs): ibuprofen can increase bleeding risk. - Other sympathomimetics: additive cardiovascular stimulation.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: pseudoephedrine may reduce their efficacy. - Diuretics: may enhance pseudoephedrine‑induced blood pressure elevation. - SSRIs or SNRIs: combined use with ibuprofen may raise bleeding risk.